Integra LifeSciences Holdings Corporation - Common Stock (IART)
25.58
0.00 (0.00%)
Integra LifeSciences is a global medical technology company that specializes in regenerative therapies and neurosurgical products
The company focuses on developing innovative solutions for healthcare providers, particularly in the areas of wound healing, neurosurgery, and reconstructive surgery. Integra's product portfolio includes a range of advanced biomaterials, surgical instruments, and specialized medical devices designed to enhance patient outcomes and support surgical procedures. By leveraging cutting-edge technologies, the company aims to address complex medical challenges and improve the quality of life for patients worldwide.
PHILADELPHIA, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Grabar Law Office is investigating whether the Board of Directors of Integra LifeSciences Holdings Corp. (NASDAQIART) breached their fiduciary duties owed to the Company.
Kaskela Law LLC announces that it has commenced an investigation into Integra LifeSciences Holdings Corp. (NASDAQIART) (“Integra”) on behalf of the company’s long-term shareholders.
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Integra LifeSciences Holdings Corporation (NasdaqGS: IART).
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Integra LifeSciences Holdings Corporation (NasdaqGS: IART).
NEW YORK, March 27, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating whether the Board of Directors of Integra Lifesciences Holdings Corp (NASDAQIART) (“Integra”) potentially breached their fiduciary duties to shareholders. Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
NEW YORK, Dec. 14, 2023 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Integra LifeSciences Holdings Corp. (NASDAQIART) on behalf of long-term stockholders following a class action complaint that was filed against Integra on September 12, 2023 with a Class Period from March 11, 2019 to May 22, 2023. Our investigation concerns whether the board of directors of Integra have breached their fiduciary duties to the company.
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, reminds investors that a class action lawsuit has been filed against Integra LifeSciences Holdings Corp. (“Integra” or the “Company”) (NASDAQIART) in the United States District Court for the District of New Jersey on behalf of all persons and entities who purchased or otherwise acquired Integra securities between March 11, 2019 and May 22, 2023, both dates inclusive (the “Class Period”). Investors have until November 13, 2023 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until November 13, 2023 to file lead plaintiff applications in a securities class action lawsuit against Integra LifeSciences Holdings Corporation (NasdaqGS: IART), if they purchased the Company’s shares between March 11, 2019 and May 22, 2023, inclusive (the “Class Period”). This action is pending in the United States District Court for the District of New Jersey.
The Law Offices of Frank R. Cruz reminds investors of the upcoming November 13, 2023 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who acquired Integra LifeSciences Holdings Corporation (“Integra” or the “Company”) (NASDAQIART) common stock between March 11, 2019 and May 22, 2023, inclusive (the “Class Period”).
If you purchased or acquired securities in Integra stock or options between March 11, 2019 and May 22, 2023 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). You may also click here for additional information: www.faruqilaw.com/IART.
NEW YORK, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, reminds investors that a class action lawsuit has been filed against Integra LifeSciences Holdings Corp. (“Integra” or the “Company”) (NASDAQIART) in the United States District Court for the District of New Jersey on behalf of all persons and entities who purchased or otherwise acquired Integra securities between March 11, 2019 and May 22, 2023, both dates inclusive (the “Class Period”). Investors have until November 13, 2023 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
San Diego, CA -- (SBWIRE) -- 11/06/2023 -- The Shareholders Foundation announced that a deadline is coming up on November 13, 2023 in the lawsuit filed for certain investors of Integra LifeSciences Holdings Corporation (NASDAQIART).
NEW YORK, Nov. 05, 2023 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Integra LifeSciences Holdings Corporation (NASDAQIART) between March 11, 2019 and May 22, 2023, both dates inclusive (the “Class Period”), of the important November 13, 2023 lead plaintiff deadline.
If you purchased or acquired securities in Integra stock or options between March 11, 2019 and May 22, 2023 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). You may also click here for additional information: www.faruqilaw.com/IART.
NEW YORK, Nov. 03, 2023 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, reminds investors that a class action lawsuit has been filed against Integra LifeSciences Holdings Corp. (“Integra” or the “Company”) (NASDAQIART) in the United States District Court for the District of New Jersey on behalf of all persons and entities who purchased or otherwise acquired Integra securities between March 11, 2019 and May 22, 2023, both dates inclusive (the “Class Period”). Investors have until November 13, 2023 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
WHY: NEW YORK, NY - (NewMediaWire) - November 01, 2023 - Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Integra LifeSciences Holdings Corporation (NASDAQIART) between March 11, 2019 and May 22, 2023, both dates inclusive (the “Class Period”), of the important November 13, 2023 lead plaintiff deadline.
Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Integra LifeSciences Holdings Corporation (“Integra” or “the Company”) (NASDAQIART) and certain of its officers.
